{"chunk_id": "medquad__chunk_47958", "source": "medquad", "text": "70 percent of patients. SSAs also reduce tumor size in around 0 to 50 percent of patients but only to a modest degree. Several studies have shown that SSAs are safe and effective for long-term treatment and in treating patients with acromegaly caused by nonpituitary tumors. Long-acting SSAs are given by intramuscular injection once a month.\n                \nDigestive problems-such as loose stools, nausea, and gas-are a side effect in about half of people taking SSAs. However, the effects are us"}